BRAF and non-small cell lung carcinoma: BRAF V600E mutations occur in 1–3% of NSCLC, and targeted therapy with dabrafenib plus trametinib demonstrates efficacy in metastatic disease, with early-phase trials now exploring their role after resection [26,27].